Search

Displaying results 71 - 80 of 308 in total
  1. Drug

    Anti-CD7 CAR T-cell therapy

    go.drugbank.com/drugs/DB18128
    Experimental

    Synonyms: A chimeric antigen receptor (CAR) immunotherapy directed against the target protein CD7
  2. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    Talquetamab is a IgG4-PAA bispecific G protein-coupled receptor class C group 5 member D (GPRC5D)-directed CD3 T-cell engager. … [L47765] Talquetamab binds to GPRC5D, a cell surface receptor expressed predominantly on multiple myeloma cells, and CD3 on T cells.

    Synonyms: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL, IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL
  3. Drug

    Letetresgene autoleucel

    go.drugbank.com/drugs/DB17233
    Investigational

    Synonyms: NY-ESO-1 T cell receptor
  4. Drug

    Anti-CD4 CAR T-cell therapy

    go.drugbank.com/drugs/DB17281
    Experimental

    Synonyms: chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells
  5. Drug

    Solrikitug

    go.drugbank.com/drugs/DB19301
    Investigational

    Solrikitug is under investigation in clinical trial NCT06496607 (A Study to Evaluate Solriktug in Adult Participants With Asthma).

    Synonyms: Immunoglobulin G1-kappa, anti-[Homo sapiens CRLF2 (cytokine receptor like factor 2,TSLP, thymic stromal lymphopoietin)], humanized monoclonal antibody
  6. Drug

    Romlusevimab

    go.drugbank.com/drugs/DB16494
    Investigational

    Romlusevimab (BRII-198) was under investigation in clinical trials (NCT04479644 and NCT04691180) to treat COVID-19, focusing on its safety, tolerability, and pharmacokinetics.

    Synonyms: IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN,RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONALANTIBODY
  7. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. … [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt

  8. Drug

    WU-CART-007

    go.drugbank.com/drugs/DB18617
    Investigational

    WU-CART-007 consists of allogeneic, fratricide-resistant genetically modified T cells transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7.

    Synonyms: an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7
  9. Drug

    Bilberry

    go.drugbank.com/drugs/DB14235
    ApprovedWithdrawn

    Synonyms: Myrtilli fructus recens (vaccinium myrtillus l.)
  10. Drug

    Amubarvimab

    go.drugbank.com/drugs/DB16493
    Investigational

    Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBODY